Unicycive Therapeutics (NASDAQ:UNCY) announced positive initial results from the patient reported outcome survey conducted during its pivotal clinical trial of oxylanthanum carbonate (OLC) in patients with hyperphosphatemia and chronic kidney disease requiring dialysis.
Survey respondents preferred OLC more than four to one over their prior phosphate binder therapy and stated that the median daily pill burden was reduced to half after switching to OLC. The company reports that OLC outperformed other phosphate binders in all categories including ease of use and preferred therapy.
In a statement, Shalabh Gupta, M.D., CEO of Unicycive, said, “In the design of our pivotal clinical trial for OLC, we believed that it was important to consider the patient perspective and the personal challenges that they face in managing their hyperphosphatemia.”
“Our focus is now directed toward filing our new drug application and making OLC available to patients who may benefit from its potential best-in-class profile, if approved,” he added.
